{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:51:53Z","timestamp":1788187913344,"version":"build-2803163510"},"reference-count":58,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2434,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1111\/j.1529-8019.2008.01213.x","type":"journal-article","created":{"date-parts":[[2009,2,18]],"date-time":"2009-02-18T02:44:00Z","timestamp":1234925040000},"page":"22-33","source":"Crossref","is-referenced-by-count":20,"title":["Long-term efficacy of biologics in dermatology"],"prefix":"10.1155","volume":"22","author":[{"given":"Leslie","family":"Castelo-Soccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby S.","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","reference":[{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB3","unstructured":"3.\u2002 Mease P , Ory P , Sharp J , et\u2003al. Adalimimab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis, published online August 6, 2008. http:\/\/ard.bmj.com\/cgi\/rapidpdf\/ard.2008.092767v1 (accessed January 14, 2009)."},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB4","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archderm.139.12.1563","article-title":"Treatment of psoriasis with alefacept: correlation of clinical improvement with reduction Sin memory T-cell counts","volume":"139","author":"Gordon","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB5","first-page":"719","article-title":"An international, randomized, double blind, placebo controlled phase III trial of intramuscular alefacept in patients with chronic plaque psoriasis","volume":"139","author":"Loebwohl","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00403-006-0660-6","article-title":"The long term efficacy and safety of new biological therapies for psoriasis","volume":"298","author":"Papp","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaad.2005.10.006","article-title":"The efficacy of multiple course of alefacept in patients with moderate to severe chronic plaque psoriasis","volume":"54","author":"Menter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2005.12.007","article-title":"An integrated analysis of thirteen trials summarizing the long term safety of alefacept in psoriasis patients who have received up to nine courses of therapy","volume":"27","author":"Goffe","year":"2005","journal-title":"Clin Ther"},{"issue":"5","key":"10.1111\/j.1529-8019.2008.01213.x-BIB9","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1468-3083.2008.02680.x","article-title":"An open label pilot study of alefacept for the treatment of pyoderma gangrenosum","volume":"22","author":"Foss","year":"2008","journal-title":"J Eur Acad Derm Venerol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"for the Efalizumab Study Group. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB12","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.jaad.2005.12.018","article-title":"the Efalizumab Study Group. Long term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial","volume":"54","author":"Gottlieb","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB13","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1365-2133.2008.08548.x","article-title":"Efalizumab: results of a 3-year continuous dosing study for long term control of psoriasis","volume":"158","author":"Leonardi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB14","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1365-2133.2007.07765.x","article-title":"Long term treatment of plaque psoriasis with efalizumab: an Italian experience","volume":"156","author":"Constanzo","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB15","unstructured":"15.\u2002 Barron H . Important Drug Warning Regarding Raptiva (Efalizumab), October 2008. http:\/\/www.gene.com\/gene\/products (accessed January 14, 2009)."},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB16","unstructured":"16.\u2002 Barron H . Dear healthcare provider letter regarding an a reported case of PML in a raptiva patient, November 2008. http:\/\/www.gene.com\/gene\/products\/information\/immunological\/raptiva\/ (accessed January 14, 2009)."},{"issue":"2","key":"10.1111\/j.1529-8019.2008.01213.x-BIB17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for treatment of psoriatic arthritis","volume":"11","author":"Papp","year":"2007","journal-title":"J Cut Med Surg"},{"issue":"6","key":"10.1111\/j.1529-8019.2008.01213.x-BIB18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09546630600967406","article-title":"New-onset debilitating arthritis in psoriasis patients receiving efalizumab","volume":"17","author":"Meyers","year":"2006","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"10.1111\/j.1529-8019.2008.01213.x-BIB19","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.23507","article-title":"Onset of psoriatic arthritis in patients treated with efalizuman for moderate to severe psoriasis","volume":"58","author":"Viguier","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB20","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jaad.2006.10.957","article-title":"Lichen planus responding to efalizumab","volume":"56","author":"Bohm","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2008.01213.x-BIB21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaad.2006.05.062","article-title":"Treatment of alopecia areata partim universalis with efalizumab","volume":"55","author":"Kaelin","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2008.01213.x-BIB22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2007.10.645","article-title":"Subcutaneous efalizumab is not effective in the treatment of alopecia areata","volume":"58","author":"Price","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB23","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archderm.143.6.719","article-title":"Long term safety and efficacy of 50\u2003mg of etanercept twice weekly in patients with psoriasis","volume":"143","author":"Tyring","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1111\/j.1529-8019.2008.01213.x-BIB25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00128071-200708030-00002","article-title":"Efficacy and Safety of etanercept in psoriasis\/psoriatic arthritis: an updated review","volume":"8","author":"Romero-Mate","year":"2007","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1111\/j.1529-8019.2008.01213.x-BIB26","first-page":"1177","article-title":"Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension","volume":"159","author":"Van de Kerkhof","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB27","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept monotherapy in psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"NEJM"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.09.002","article-title":"A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis","volume":"56","author":"Moore","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB29","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-2133.2008.08564.x","article-title":"Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24 week, randomized, controlled, investigator-blinded pilot trial","volume":"158","author":"Gisondi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB30","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB31","first-page":"727","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"38","author":"Yazici","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept treatment for children and adolescents with plaque psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"NEJM"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in management of hidradenitis suppurativa","volume":"154","author":"Cusak","year":"2006","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1111\/j.1529-8019.2008.01213.x-BIB35","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1468-3083.2008.02617.x","article-title":"Long term efficacy of etanercept in hidradenitis suppurativa","volume":"22","author":"Zangrilli","year":"2008","journal-title":"J Euro Acad Dermatol Veneral"},{"issue":"4","key":"10.1111\/j.1529-8019.2008.01213.x-BIB36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis concurrent and hepatitis c virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1111\/j.1529-8019.2008.01213.x-BIB37","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2005.11.1035","article-title":"Etanercept in 2 patients with psoriasis and concomitant hepatitis C","volume":"54","author":"De Simone","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over one year in the treatment of moderate to severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"9494","key":"10.1111\/j.1529-8019.2008.01213.x-BIB39","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance for moderate to severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1111\/j.1529-8019.2008.01213.x-BIB40","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefit of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: result from the Infliximab Multinational Psoriatic Athritis Controlled Trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Athritis Rheum"},{"issue":"5","key":"10.1111\/j.1529-8019.2008.01213.x-BIB41","first-page":"869","article-title":"Two year efficacy and safety of infliximab treatment in patients with acute psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)","volume":"35","author":"Antoni","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2004.11.022","article-title":"Infliximab in the treatment of moderate to severe atopic dermatitis","volume":"2","author":"Jacobi","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB43","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1529-8019.2007.00142.x","article-title":"The use of IVIG therapy in dermatology","volume":"20","author":"Fernandez","year":"2007","journal-title":"Dermatologic Therapy"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB44","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous Immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB45","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2133.2007.08217.x","article-title":"Treatment of pyoderma gangrenosum with intravenous immunoglobulin","volume":"157","author":"Cummins","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB46","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB47","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","article-title":"High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases","volume":"56","author":"Segura","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2133.2007.08069.x","article-title":"Intramuscular immunoglobulin for recalcitrant suppurative diseases of the skin: a retrospective review of 63 cases","volume":"157","author":"Goo","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2133.1998.02033.x","article-title":"Intravenous immunoglobulin in autoimmune chronic urticaria","volume":"138","author":"O'Donnell","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB50","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immunoglobulin as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.intimp.2005.11.016","article-title":"The role of high-dose immunoglobulin intravenous in the treatment of dermatomyositis","volume":"6","author":"Dalakus","year":"2006","journal-title":"Int Immunopharm"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"for the TEN-IVIG study group. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulin: multi-center retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2008.01213.x-BIB53","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non-comparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB55","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematous","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB57","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1529-8019.2008.01213.x-BIB58","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int J Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2008.01213.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2008.01213.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:57:22Z","timestamp":1671818242000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2008.01213.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2008.01213.x","relation":{},"ISSN":["1396-0296","1529-8019"],"issn-type":[{"value":"1396-0296","type":"print"},{"value":"1529-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}